FDA Panel Backs 6 of 7 Peptides, Rejects DSIP

The Two-Day Result

The FDA Pharmacy Compounding Advisory Committee met for two days, July 23 and 24, 2026, to review seven peptides for the 503A bulks list. That is the list of bulk drug substances that licensed 503A pharmacies are cleared to compound from for individual patients. When the meeting closed on Friday afternoon, the committee had recommended six of the seven. On Day 1 it backed BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , KPV, TB-500, and MOTS-C Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide . On Day 2 it added Semax Explore PeRxSemax/SelankCognitive Clarity & Calm FocusView peptide and Epitalon Explore PeRxEpitalonThe Longevity PeptideView peptide . It declined to recommend only one: Emideltide, better known as DSIP Explore PeRxDSIPDeep Sleep PeptideView peptide . When you get a peptide through PeRx, it is prescribed by a licensed provider and compounded in a US-based, FDA-regulated 503A pharmacy, the same regulated pathway many everyday prescriptions go through.

The two most useful things to hold onto are these. First, a recommendation is a signal, not a switch: nothing about legality or day-to-day access flipped on the day of a vote. Second, the single rejection, DSIP, was not banned. Declining to recommend a peptide for the bulks list is a different action from restricting it, and DSIP remains exactly where it was the week before the meeting.

Every Vote, Peptide by Peptide

For a plain-language explainer of the categories behind these votes, how removal from Category 2 differs from being added to the 503A bulks list, and why neither equals FDA approval, see our dated FDA peptide review timeline. If you are trying to sort the headlines, our guide on whether the FDA is banning peptides in 2026 Read nextWill the FDA Ban Peptides in 2026? What the Data SaysSearch "FDA peptide ban" and you will find panic in one direction and "they're legal again!" in the other. Both are wrong. Here is the precise, physician-reviewed answer to whether the FDA is banning peptides in 2026, and what the actual regulatory record shows.Read article walks through the two loudest myths.

What Happened on July 24

Day 2 covered the three peptides left on the agenda: Semax, Epitalon, and Emideltide (DSIP). The committee recommended Semax in an 8-5 vote. The proposal in front of the panel cited uses studied in the older clinical literature, including cerebral ischemia and migraine. It recommended Epitalon in a 7-4 vote, tied to its studied role in sleep. Both followed the Day 1 pattern: the panel weighed the evidence and stakeholder input and recommended inclusion, over the objection of FDA staff.

The exception was Emideltide, the compounding name for DSIP. Here the committee split the other way, voting 6-7 against recommending it for the bulks list. It was the only no of the two-day meeting, and it was close. At least one panelist raised concerns about downstream effects that the available data could not rule out. That single vote is the reason the final headline is "six of seven" rather than a clean sweep.

The One Rejection: DSIP

Because DSIP is the outlier, it is worth being precise about what the vote did and did not do. The committee declined to recommend DSIP for the 503A bulks list. That is a rejected recommendation. It is not a ban, not a recall, and not a scheduling action. DSIP was removed from the restricted Category 2 list in April 2026, and it is in the same gray zone today as it was before the meeting: not restricted, not on the bulks list, and not FDA-approved.

The Panel Overruled the FDA’s Scientists

The most notable thread across both days was not simply that the panel said yes six times. It was that every one of those yeses ran against the FDA’s own recommendation. Ahead of the meeting, FDA staff published briefing documents that reached the same conclusion for each of the seven peptides: do not add them to the 503A bulks list. Staff applied the four-factor framework the agency uses for these decisions, physical and chemical characterization, historical use in compounding, evidence of effectiveness, and safety, and concluded that none of the seven met the bar.

The advisory committee is a separate body of outside experts. It weighed the same evidence together with stakeholder and patient testimony and landed on the opposite recommendation for six of the seven. That split, agency scientists on one side and the advisory panel on the other, is why the meeting drew national coverage. It is also why the precise wording matters: a recommendation that runs against staff analysis is a strong signal of where the debate is heading, but it does not carry the force of a rule.

What the Votes Do Not Change

It is easy to read a run of "yes" votes as "peptides are legal now," or a "no" vote as "DSIP is banned." Neither is what happened. Three things did not change on July 23 or 24.

Legality did not change. These peptides were not banned the day before the meeting, and the six are not newly legal the day after. Since April 2026 they have sat in a regulatory gray zone: removed from the restricted Category 2 list, but not yet added to the 503A bulks list, and not FDA-approved. The votes are a step in the process that could eventually add six of them to that list. They are not the addition itself.

FDA approval did not happen. None of these peptides is an FDA-approved drug, and this meeting was never about approval. The 503A bulks list is a compounding pathway, not a marketing approval. A compounded medication is prepared by a licensed pharmacy for a specific patient under a prescription; an FDA-approved drug has completed formal clinical trials for a specific indication. Those are different things, and the votes touched only the first.

Day-to-day access did not change. Patients who work with a licensed provider already access these peptides, including DSIP, through a valid prescription filled by a licensed 503A compounding pharmacy. That pathway does not depend on the bulks-list label, so it is exactly the same today as it was last week.

What Happens Next

The committee recommends; the FDA decides. The agency is not bound by the panel, though it has historically weighed advisory recommendations heavily. To actually add a peptide to the 503A bulks list, the FDA has to complete formal notice-and-comment rulemaking: publish a proposed rule, open a public comment period, review the comments, and issue a final rule. That sequence routinely takes more than a year. So even after favorable votes, the realistic horizon for a practical change in compounding access runs into 2027.

There is also more still on the calendar. Five of the twelve peptides removed from Category 2 in April 2026, LL-37, GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide (injectable), Dihexa, Melanotan II, and PEG-MGF, were not part of this meeting. They are slated for a later advisory panel scheduled before the end of February 2027. In other words, the July meeting closed one chapter of the review, not the whole book.

What It Means for You

If you already use peptide therapy through a provider, nothing about your prescription, your pharmacy, or your access changed because of these votes. That is true whether you use one of the six the panel recommended or DSIP, the one it did not. If you have been watching the headlines and waiting for peptides to become "legal," the honest read is that the process moved a real step forward on July 23 and 24, but it is still a process, with rulemaking ahead and no instant change.

The steadier takeaway is the one that has been true throughout: the safest way to use these peptides, whatever the FDA ultimately decides, is under a licensed provider who prescribes a protocol suited to you, filled by a licensed pharmacy that tests what it ships. That is the pathway PeRx uses. For the full regulatory backstory, our FDA peptide review timeline and our July 2026 FDA peptide panel guide Read nextJuly 2026 FDA Peptide Panel: BPC-157 ReviewOn July 23-24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides, including BPC-157, TB-500, and Semax. Despite the headlines, this is not a ban, and these peptides are not suddenly "legal again" either. Here is the precise, physician-reviewed picture of where things actually stand and what it means if you use peptide therapy.Read article lay out how the pieces fit together. Each order ships fully reconstituted and ready to use, delivered overnight in refrigerated packaging, with nothing to mix on your end.

FDA Panel Backs 6 of 7 Peptides, Rejects DSIP: Common Questions